Osteoporosis and hormone replacement therapy

Hormone replacement therapy and the prevention of postmenopausal osteoporosis

Fracture prevention is one of the public health priorities worldwide. Estrogen deficiency is the major factor in the pathogenesis of postmenopausal osteoporosis, the most common metabolic bone disease. Different effective treatments for osteoporosis are available. Hormone replacement therapy (HRT) at different doses rapidly normalizes turnover, preserves bone mineral density (BMD) at all skelet...

Alternate options to hormone replacement therapy for osteoporosis.

This presentation, developed from a symposium lecture at the 40th Annual Convention of the American College of Osteopathic Family Physicians on March 22, 2003, in Nashville, Tenn, highlights three pivotal studies that have altered the preferred option for the treatment and prevention of osteoporosis in post-menopausal women. The Heart Estrogen/progestin Replacement Study (HERS), the HERS II, an...

Hormone Replacement Therapy and Stroke

Despite major progress in treatment and prevention, stroke remains the leading cause of disability and the third leading cause of death, surpassed only by heart disease and cancer, in the United States.1 An estimated 500 000 to 600 000 first and 100 000 recurrent strokes occur each year, and '160 000 of these are fatal.2 Among stroke survivors, the burden of long-term disability is great. In th...

Hormone replacement therapy.

HRT is indicated for the treatment of moderate ▪ to severe vasomotor and urogenital symptoms associated with menopause. HRT is not recommended for primary prevention of ▪ disease because of increased risk of other adverse events. The use of HRT increases the risk of stroke, venous ▪ thromboembolism (VTE) and gall bladder disease and combined oestrogen progestogen therapy is also associated with...

Hormone replacement therapy.